Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous pemphigoid (BP) in adults. The drug is now the only targeted medicine ...

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management. Quiver AI Summary The U.S. Food and Drug Administration (FDA) has approved ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and ...

Dr. Radhika Banka, Consultant, Respiratory Physician at PD Hinduja Hospital & Medical Research Centre, Mahim, told IndiaToday ...

Dr. Radhika Banka, Consultant, Respiratory Physician at P.D. Hinduja Hospital, Mahim, tells India Today 10 ways how smoking ...

Vaping may seem cool to young kids and teenager, but it can have a lasting impact on their health. This 24-year-old took to ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

Unlike a bulla, which is a distal acinar (or paraseptal) emphysematous lung lesion, the displacement caused by subpleural interstitial emphysema is generally small in size, i.e., 1-2 cm in diameter ...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions ...

Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, ...

Exposure to air pollution, other contaminants and traditional herbal medicines may be contributing to the development of lung ...